Study of Biological Activity of Novel Hydroxamic Acids Derived From Vorinostat as the Inhibitor of Histone Deacetylases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F22%3A00126408" target="_blank" >RIV/00216224:14160/22:00126408 - isvavai.cz</a>
Result on the web
<a href="https://sciendo.com/issue/afpuc/69/s1" target="_blank" >https://sciendo.com/issue/afpuc/69/s1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2478/afpuc-2022-0009" target="_blank" >10.2478/afpuc-2022-0009</a>
Alternative languages
Result language
angličtina
Original language name
Study of Biological Activity of Novel Hydroxamic Acids Derived From Vorinostat as the Inhibitor of Histone Deacetylases
Original language description
Histone deacetylase inhibitors (iHDACs), a class of epigenetic regulators, are substances with anticancer activity that is associated with inhibition of cell proliferation, induction of programmed cell death, inhibition of angiogenesis, and induction of the cytodifferentiation process in cancer cells. Hydroxamic acid derivatives are currently the most important group of iHDACs. Our study was focused on the evaluation of biological activity of new hydroxamic acids derivates as potential iHDACs designed and synthesised by the Department of Chemical Drugs in Faculty of Pharmacy at Masaryk University.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů